第七十七篇：FDA 核准 Ozempic 用於降低糖尿病患者的慢性腎病風險

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
FDA 核准 Ozempic 用於降低糖尿病患者的慢性腎病風險

本週精選文來自：CNN

點此前往閱讀全文

★Vocabulary

1. clinical trial 臨床試驗
2. semaglutide 司美格魯肽(藥品名稱)
3. kidney failure 腎衰竭
4. chronic kidney disease 慢性腎臟疾病
5. complication 併發症
6. efficacy 療效
7. inhibitor 抑制劑
8. indication 適應症
9. endpoint 終點
10. renal clinic 腎臟科診所
11. uptake 吸收率
12. clinician 臨床醫師

#里茲螞蟻文法課 必教句型

• #介係詞
  The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set of specific medical conditions that it may be prescribed to treat.
  FDA 於週二批准的新適應症使 Ozempic 成為該類藥物中適應範圍最廣的藥物，可用於治療最多種的特定醫療狀況。
• #時態-現在完成式
  Ozempic and other semaglutide injections such as Wegovy have been in short supply for years due to their rapid popularity.
  由於需求大增，Ozempic 及 Wegovy 等其他司美格魯肽注射劑多年來一直供不應求。